{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:30:57Z","timestamp":1789086657041,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TR 209"],"award-info":[{"award-number":["SFB\/TR 209"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003542","name":"Ministerium f\u00fcr Wissenschaft, Forschung und Kunst Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","award":["32-5400\/58\/2"],"award-info":[{"award-number":["32-5400\/58\/2"]}],"id":[{"id":"10.13039\/501100003542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["eMED, multiscale HCC"],"award-info":[{"award-number":["eMED, multiscale HCC"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Baden-W\u00fcrttemberg for Economic Affairs, Labor and Tourism"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibroblast growth factor receptor (FGFR)\u22122 can be inhibited by FGFR-selective or non-selective tyrosine kinase inhibitors (TKIs). Selective TKIs are approved for cholangiocarcinoma (CCA) with FGFR2 fusions; however, their application is limited by a characteristic pattern of adverse events or evocation of kinase domain mutations. A comprehensive characterization of a patient cohort treated with the non-selective TKI lenvatinib reveals promising efficacy in FGFR2-driven CCA. In a bed-to-bench approach, we investigate FGFR2 fusion proteins bearing critical tumor-relevant point mutations. These mutations confer growth advantage of tumor cells and increased resistance to selective TKIs but remain intriguingly sensitive to lenvatinib. In line with clinical observations, in-silico analyses reveal a more favorable interaction pattern of lenvatinib with FGFR2, including an increased flexibility and ligand efficacy, compared to FGFR-selective TKIs. Finally, the treatment of a patient with progressive disease and a newly developed kinase mutation during therapy with a selective inhibitor results in a striking response to lenvatinib. Our in vitro, in silico, and clinical data suggest that lenvatinib is a promising treatment option for FGFR2-driven CCA, especially when insurmountable adverse reactions of selective TKIs or acquired kinase mutations occur.<\/jats:p>","DOI":"10.1038\/s41467-024-45247-6","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T13:02:15Z","timestamp":1707742935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-5955","authenticated-orcid":false,"given":"Stephan","family":"Spahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Kleinhenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-0740","authenticated-orcid":false,"given":"Ekaterina","family":"Shevchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-9564","authenticated-orcid":false,"given":"Aaron","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Rasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ruhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Klaumuenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6933-7590","authenticated-orcid":false,"given":"Thales","family":"Kronenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-1486","authenticated-orcid":false,"given":"Stefan A.","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Sundberg-Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khac Cuong","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-5479","authenticated-orcid":false,"given":"Marius","family":"Horger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Biskup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1443-2720","authenticated-orcid":false,"given":"Klaus","family":"Schulze-Osthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Templin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisar P.","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4196-4204","authenticated-orcid":false,"given":"Antti","family":"Poso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-8263","authenticated-orcid":false,"given":"Michael","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"45247_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557\u2013588 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"45247_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"S Rizvi","year":"2018","unstructured":"Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15, 95\u2013111 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"45247_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y. & Zhu, A. X. Biliary tract cancer. Lancet 397, 428\u2013444 (2021).","journal-title":"Lancet"},{"key":"45247_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"key":"45247_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","volume":"7","author":"JW Valle","year":"2017","unstructured":"Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J. & Zhu, A. X. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 7, 943\u2013962 (2017).","journal-title":"Cancer Discov."},{"key":"45247_CR6","doi-asserted-by":"crossref","unstructured":"Bitzer, M., et al. Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. JCO Precis. Oncol., 4, 258\u2013271 (2020).","DOI":"10.1200\/PO.19.00359"},{"key":"45247_CR7","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke, C. J., Munoz-Garrido, P. & Andersen, J. B. Molecular Targets in Cholangiocarcinoma. Hepatology 73, 62\u201374 (2021).","DOI":"10.1002\/hep.31278"},{"key":"45247_CR8","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.3390\/cancers12113370","volume":"12","author":"N Personeni","year":"2020","unstructured":"Personeni, N. et al. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers 12, 3370 (2020).","journal-title":"Cancers"},{"key":"45247_CR9","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.3390\/cancers12082190","volume":"12","author":"I Malenica","year":"2020","unstructured":"Malenica, I., Donadon, M. & Lleo, A. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. Cancers 12, 2190 (2020).","journal-title":"Cancers"},{"key":"45247_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","volume":"6","author":"AE Kam","year":"2021","unstructured":"Kam, A. E., Masood, A. & Shroff, R. T. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol. Hepatol. 6, 956\u2013969 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"45247_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7087","volume":"6","author":"D Sia","year":"2015","unstructured":"Sia, D. et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun. 6, 6087 (2015).","journal-title":"Nat. Commun."},{"key":"45247_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales, J. M. et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261\u2013280 (2016).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"45247_CR13","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai, Y. et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59, 1427\u20131434 (2014).","journal-title":"Hepatology"},{"key":"45247_CR14","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery, M. A. et al. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clin. Cancer Res. 24, 4154\u20134161 (2018).","journal-title":"Clin. Cancer Res."},{"key":"45247_CR15","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","volume":"45","author":"RP Graham","year":"2014","unstructured":"Graham, R. P. et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol. 45, 1630\u20131638 (2014).","journal-title":"Hum. Pathol."},{"key":"45247_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy, S. M. Pemigatinib: First Approval. Drugs 80, 923\u2013929 (2020).","journal-title":"Drugs"},{"key":"45247_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","volume":"81","author":"C Kang","year":"2021","unstructured":"Kang, C. Infigratinib: First Approval. Drugs 81, 1355\u20131360 (2021).","journal-title":"Drugs"},{"key":"45247_CR18","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","volume":"11","author":"JM Cleary","year":"2021","unstructured":"Cleary, J. M. et al. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 11, 2488\u20132505 (2021).","journal-title":"Cancer Discov."},{"key":"45247_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"45247_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle, M. et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol. Hepatol. 6, 803\u2013815 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"45247_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal, L. et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N. Engl. J. Med. 388, 228\u2013239 (2023).","journal-title":"N. Engl. J. Med."},{"key":"45247_CR22","doi-asserted-by":"crossref","unstructured":"Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat. Rev. Clin. Oncol. 16, 105\u2013122 (2018).","DOI":"10.1038\/s41571-018-0115-y"},{"key":"45247_CR23","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1042\/BST20180004","volume":"46","author":"B Farrell","year":"2018","unstructured":"Farrell, B. & Breeze, A. L. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. Biochem Soc. Trans. 46, 1753\u20131770 (2018).","journal-title":"Biochem Soc. Trans."},{"key":"45247_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00220-0","volume":"5","author":"M Bitzer","year":"2021","unstructured":"Bitzer, M. et al. Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma. npj Precis. Oncol. 5, 80 (2021).","journal-title":"npj Precis. Oncol."},{"key":"45247_CR25","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","volume":"151","author":"R Roskoski Jr.","year":"2020","unstructured":"Roskoski, R. Jr. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharm. Res. 151, 104567 (2020).","journal-title":"Pharm. Res."},{"key":"45247_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/cells8060614","volume":"8","author":"S Dai","year":"2019","unstructured":"Dai, S., Zhou, Z., Chen, Z., Xu, G. & Chen, Y. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells 8, 614 (2019).","journal-title":"Cells"},{"key":"45247_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01100-3","volume":"23","author":"G King","year":"2021","unstructured":"King, G. & Javle, M. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Curr. Oncol. Rep. 23, 108 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"45247_CR28","doi-asserted-by":"publisher","first-page":"e1004135","DOI":"10.1371\/journal.pgen.1004135","volume":"10","author":"MJ Borad","year":"2014","unstructured":"Borad, M. J. et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 10, e1004135 (2014).","journal-title":"PLoS Genet"},{"key":"45247_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto, Y. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc. Cell 6, 18 (2014).","journal-title":"Vasc. Cell"},{"key":"45247_CR30","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","volume":"25","author":"R Bahleda","year":"2019","unstructured":"Bahleda, R. et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin. Cancer Res. 25, 4888\u20134897 (2019).","journal-title":"Clin. Cancer Res."},{"key":"45247_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","volume":"120","author":"V Mazzaferro","year":"2019","unstructured":"Mazzaferro, V. et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br. J. Cancer 120, 165\u2013171 (2019).","journal-title":"Br. J. Cancer"},{"key":"45247_CR32","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.3390\/cancers13122968","volume":"13","author":"A Kommalapati","year":"2021","unstructured":"Kommalapati, A., Tella, S. H., Borad, M., Javle, M. & Mahipal, A. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers 13, 2968 (2021).","journal-title":"Cancers"},{"key":"45247_CR33","doi-asserted-by":"publisher","first-page":"103091","DOI":"10.1016\/j.critrevonc.2020.103091","volume":"155","author":"A Mahipal","year":"2020","unstructured":"Mahipal, A., Tella, S. H., Kommalapati, A., Yu, J. & Kim, R. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit. Rev. Oncol. Hematol. 155, 103091 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"45247_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal, L. et al. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 7, 252\u2013263 (2017).","journal-title":"Cancer Discov."},{"key":"45247_CR35","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","volume":"9","author":"L Goyal","year":"2019","unstructured":"Goyal, L. et al. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 9, 1064\u20131079 (2019).","journal-title":"Cancer Discov."},{"key":"45247_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","volume":"11","author":"IM Silverman","year":"2021","unstructured":"Silverman, I. M. et al. Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. Cancer Discov. 11, 326\u2013339 (2021).","journal-title":"Cancer Discov."},{"key":"45247_CR37","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","volume":"19","author":"MA Krook","year":"2020","unstructured":"Krook, M. A. et al. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Mol. Cancer Ther. 19, 847\u2013857 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"45247_CR38","first-page":"1079","volume":"4","author":"DD Von Hoff","year":"1998","unstructured":"Von Hoff, D. D. There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 4, 1079\u20131086 (1998).","journal-title":"Clin. Cancer Res."},{"key":"45247_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon, J. et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat. Med. 25, 751\u2013758 (2019).","journal-title":"Nat. Med."},{"key":"45247_CR40","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff, D. D. et al. Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28, 4877\u20134883 (2010).","journal-title":"J. Clin. Oncol."},{"key":"45247_CR41","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","volume":"25","author":"JK Sicklick","year":"2019","unstructured":"Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744\u2013750 (2019).","journal-title":"Nat. Med."},{"key":"45247_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12852","volume":"7","author":"F Treindl","year":"2016","unstructured":"Treindl, F. et al. A bead-based western for high-throughput cellular signal transduction analyses. Nat. Commun. 7, 12852 (2016).","journal-title":"Nat. Commun."},{"key":"45247_CR43","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook, M. A. et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br. J. Cancer 124, 880\u2013892 (2021).","journal-title":"Br. J. Cancer"},{"key":"45247_CR44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","volume":"27","author":"H Chen","year":"2007","unstructured":"Chen, H. et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 27, 717\u2013730 (2007).","journal-title":"Mol. Cell"},{"key":"45247_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/MCB.00943-14","volume":"35","author":"J Hu","year":"2015","unstructured":"Hu, J. et al. Kinase regulation by hydrophobic spine assembly in cancer. Mol. Cell Biol. 35, 264\u2013276 (2015).","journal-title":"Mol. Cell Biol."},{"key":"45247_CR46","doi-asserted-by":"publisher","first-page":"14377","DOI":"10.1073\/pnas.0807988105","volume":"105","author":"AP Kornev","year":"2008","unstructured":"Kornev, A. P., Taylor, S. S. & Ten Eyck, L. F. A helix scaffold for the assembly of active protein kinases. Proc. Natl Acad. Sci. USA 105, 14377\u201314382 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45247_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","volume":"36","author":"SS Taylor","year":"2011","unstructured":"Taylor, S. S. & Kornev, A. P. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci. 36, 65\u201377 (2011).","journal-title":"Trends Biochem Sci."},{"key":"45247_CR48","doi-asserted-by":"publisher","first-page":"e1001680","DOI":"10.1371\/journal.pbio.1001680","volume":"11","author":"HS Meharena","year":"2013","unstructured":"Meharena, H. S. et al. Deciphering the structural basis of eukaryotic protein kinase regulation. PLoS Biol. 11, e1001680 (2013).","journal-title":"PLoS Biol."},{"key":"45247_CR49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen, P., Cross, D. & Janne, P. A. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov. 20, 551\u2013569 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"45247_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7150\/jca.3.7","volume":"3","author":"CH Bailey","year":"2012","unstructured":"Bailey, C. H. et al. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J. Cancer 3, 7\u201313 (2012).","journal-title":"J. Cancer"},{"key":"45247_CR51","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/annonc\/mdt278","volume":"24","author":"S Cousin","year":"2013","unstructured":"Cousin, S. et al. Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. Ann. Oncol. 24, 2681\u20132685 (2013).","journal-title":"Ann. Oncol."},{"key":"45247_CR52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard, C. et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 7, 586\u2013595 (2017).","journal-title":"Cancer Discov."},{"key":"45247_CR53","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin, H. et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730\u2013734 (2021).","journal-title":"Nature"},{"key":"45247_CR54","doi-asserted-by":"publisher","first-page":"13997","DOI":"10.1080\/07391102.2021.1997816","volume":"40","author":"R Sangeetha","year":"2022","unstructured":"Sangeetha, R., Arockia Jeya Yasmi Prabha, E., Lakshmi, A., Sangavi, P. & Langeswaran, K. Molecular docking and dynamic simulations of Ocimum basilicum compounds against HCC and structural, vibrational, quantum, and chemical investigation of campesterol. J. Biomol. Struct. Dyn. 40, 13997\u201314012 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"45247_CR55","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak, P. et al. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov. 11, 2780\u20132795 (2021).","journal-title":"Cancer Discov."},{"key":"45247_CR56","doi-asserted-by":"publisher","first-page":"e21137","DOI":"10.7554\/eLife.21137","volume":"6","author":"H Chen","year":"2017","unstructured":"Chen, H. et al. Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. Elife 6, e21137 (2017).","journal-title":"Elife"},{"key":"45247_CR57","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput Aided Mol. Des. 27, 221\u2013234 (2013).","journal-title":"J. Comput Aided Mol. Des."},{"key":"45247_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1021\/acsmedchemlett.0c00517","volume":"12","author":"RA Brawn","year":"2021","unstructured":"Brawn, R. A. et al. Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3. ACS Med Chem. Lett. 12, 93\u201398 (2021).","journal-title":"ACS Med Chem. Lett."},{"key":"45247_CR59","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki, M. et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 7, 2641\u20132653 (2018).","journal-title":"Cancer Med."},{"key":"45247_CR60","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/ci800324m","volume":"49","author":"TA Halgren","year":"2009","unstructured":"Halgren, T. A. Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model 49, 377\u2013389 (2009).","journal-title":"J. Chem. Inf. Model"},{"key":"45247_CR61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1747-0285.2007.00483.x","volume":"69","author":"T Halgren","year":"2007","unstructured":"Halgren, T. New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Des. 69, 146\u2013148 (2007).","journal-title":"Chem. Biol. Drug Des."},{"key":"45247_CR62","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner, R. A. et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med Chem. 49, 6177\u20136196 (2006).","journal-title":"J. Med Chem."},{"key":"45247_CR63","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med Chem. 47, 1739\u20131749 (2004).","journal-title":"J. Med Chem."},{"key":"45247_CR64","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med Chem. 47, 1750\u20131759 (2004).","journal-title":"J. Med Chem."},{"key":"45247_CR65","doi-asserted-by":"crossref","unstructured":"Guagnano, V. et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)\u22121-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}\u22121-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 54, 7066\u20137083 (2011).","DOI":"10.1021\/jm2006222"},{"key":"45247_CR66","doi-asserted-by":"publisher","first-page":"D562","DOI":"10.1093\/nar\/gkaa895","volume":"49","author":"GK Kanev","year":"2021","unstructured":"Kanev, G. K., de Graaf, C., Westerman, B. A., de Esch, I. J. P. & Kooistra, A. J. KLIFS: an overhaul after the first 5 years of supporting kinase research. Nucleic Acids Res. 49, D562\u2013D569 (2021).","journal-title":"Nucleic Acids Res."},{"key":"45247_CR67","doi-asserted-by":"crossref","unstructured":"Waskom M. seaborn: statistical data visualization. J. Open Source Softw. 6, 3021 (2021).","DOI":"10.21105\/joss.03021"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45247-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45247-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45247-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T13:03:21Z","timestamp":1707743001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45247-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45247"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45247-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B. reports that he received compensations as a member of scientific advisory boards of Roche Pharma AG, Incyte Biosciences Germany GmbH, Bayer Vital GmbH, Bristol-Myers Squibb, MSD Sharp & Dome, Taiho oncology Europe, outside the submitted work. The remaining authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1287"}}